Curis Inc (CRIS) stock
Close on Nov 11, 2026Market cap $1.24MP/E –Yield –
Curis Inc saw revenue fall 62.2% to $4.31M over the twelve months to Jun 30, 2026. At the latest close the market valued the company at $1.24M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $1.24M
- P/E ratio
- –
- Price to sales
- 0.29
- Price to book
- 0.26
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $4.31M
- Net income
- -$21.15M
- EPS, diluted
- -$11.60
- Book value per share
- $2.20
- Diluted shares
- 2M
Trading
- Previous close
- $0.65
- Open
- $0.64
- Day's range
- $0.56 – $0.66
- Volume
- 513,129
- Average volume (20 days)
- 12,230,786
- Beta (5 years)
- 1.95
- 52-week range
- $0.33 – $28.40
- RSI (14 days)
- 44.2
- Volatility (1 year)
- 147.3%
- Relative volume
- 0.18×
- WACC
- 14.6%
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | CRIS | S&P 500 | Difference | CRIS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -11.9% | -2.4% | −9.5 pts | ||
| 3 months | -74.4% | -1.2% | −73.2 pts | ||
| Year to date | -97.0% | +12.3% | −109.3 pts | ||
| 1 year | -97.6% | +12.4% | −110.1 pts | ||
| 3 years | -99.5% | +78.8% | −178.3 pts | -83.1% | +21.4% |
| 5 years | -100.0% | +75.2% | −175.1 pts | -81.0% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -60.7% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Curis filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Results
- Update
About Curis
Biological Products, (No Diagnostic Substances)
Curis, Inc. is a biotechnology company focused on the development of drug candidates for the treatment of cancer. The company's primary focus is emavusertib, an orally administered small molecule inhibitor targeting IRAK4 and FLT3 signaling pathways. Emavusertib is evaluated in clinical trials for hematologic malignancies, including primary central nervous system lymphoma and chronic lymphocytic leukemia. The company also holds licensed preclinical and clinical programs in immuno-oncology and precision oncology, developed through collaboration agreements. Its therapeutic candidates are primarily investigated for patients with rare or relapsed cancers.
Company profile, executives and historyCuris stock: common questions
What is Curis's stock price?
CRIS closed at $0.59 on Nov 11, 2026, down 9.42% on the day. Over the past 52 weeks it traded between $0.33 and $28.40.
What is Curis's market cap?
Curis was worth $1.24M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is CRIS's P/E ratio?
Curis lost money over fiscal 2025 (diluted EPS -$11.60), so it has no meaningful P/E ratio.
How much revenue does Curis make?
Curis reported revenue of $4.31M for the twelve months to Jun 30, 2026, down 62.2% from a year earlier.
Does Curis pay a dividend?
No. Curis has not paid a cash dividend over the last twelve months.
How has CRIS stock performed over the past year?
Including dividends, CRIS returned -97.6% over the past year, against +12.4% for the S&P 500.
How many CRIS shares are sold short?
1M shares were sold short at the latest FINRA report, 61.83% of the float, or 1.1 days of average trading volume.
Who are Curis's competitors?
Companies most similar to Curis by business, industry and size include MOLN, RLAY, IMNM, ELOX, INBX.
See a number that looks wrong?